Table 6_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.xls حسب Xiaoyu Han (550622)

"…Anagen-phase SHFs exhibit significantly increased volume, deeper dermal penetration, and active cell proliferation. …"

Table 2_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.pdf حسب Xiaoyu Han (550622)

"…Anagen-phase SHFs exhibit significantly increased volume, deeper dermal penetration, and active cell proliferation. …"

Data Sheet 1_Determination of nine prostaglandins in the arachidonic acid metabolic pathway with UHPLC-QQQ-MS/MS and application to in vitro and in vivo inflammation models.docx حسب Yufeng Huang (782683)

"…At the same time, the levels of these PGs decreased significantly (p < 0.01 vs. LPS-induced group) after the positive drug (dexamethasone) intervention. …"

Table 5_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.csv حسب Xiaoyu Han (550622)

"…Anagen-phase SHFs exhibit significantly increased volume, deeper dermal penetration, and active cell proliferation. …"

Table 3_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.pdf حسب Xiaoyu Han (550622)

"…Anagen-phase SHFs exhibit significantly increased volume, deeper dermal penetration, and active cell proliferation. …"

Table 4_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.csv حسب Xiaoyu Han (550622)

"…Anagen-phase SHFs exhibit significantly increased volume, deeper dermal penetration, and active cell proliferation. …"

Table 1_Comparative proteomic analysis of the telogen-to-anagen transition in cashmere goat secondary hair follicles.pdf حسب Xiaoyu Han (550622)

"…Anagen-phase SHFs exhibit significantly increased volume, deeper dermal penetration, and active cell proliferation. …"

Changes in the effective optical zone following hyperopic keratorefractive lenticule extraction حسب Yangyi Huang (11859382)

"…<p>To evaluate the longitudinal changes in the effective optical zone (EOZ) following hyperopic keratorefractive lenticule extraction (KLEx) and investigate factors influencing the EOZ.</p> <p>This retrospective study included 27 patients who underwent hyperopic KLEx. …"

Table 2_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.tiff حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"

Table 3_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv حسب Siying Wei (5990276)

"…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …"

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... حسب Yun Xu (139234)

"…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…"